Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-FDG-University of California, Davis refers to the specific application and research protocols involving 18F-fluorodeoxyglucose (18F-FDG) conducted at the University of California, Davis. 18F-FDG is a radiolabeled glucose analog used as a positron emission tomography (PET) tracer. It is transported into cells by glucose transporters (GLUT) and subsequently phosphorylated by the enzyme hexokinase into 18F-FDG-6-phosphate. Because this molecule cannot undergo further glycolysis, it becomes metabolically trapped within cells, allowing for the visualization and quantification of glucose metabolism. Researchers at UC Davis are utilizing the EXPLORER total-body PET/CT system to develop single-tracer multiparametric imaging solutions. This methodology aims to extract both quantitative blood flow (perfusion) and glucose metabolic rates from a single dynamic 18F-FDG PET scan using advanced tracer kinetic modeling, primarily for investigating cardiovascular diseases and myofascial pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 18F-FDG-University of California, Davis.